Aro is expanding Nucleic Acids Chemistry team to design and synthesize novel Centyrin-oligonucleotide conjugate therapeutics. In this role, you will report to Aro’s Chief Technology Officer and become a key member of the chemistry team.
Aro Biotherapeutics is an equal opportunity employer that is committed to diversity and inclusion in the workplace. We prohibit discrimination and harassment of any kind based on race, color, sex, religion, sexual orientation, gender identity/gender expression, national origin, disability, genetic information, pregnancy, or any other protected characteristic as outlined by federal, state, or local laws.
Aro Biotherapeutics offers a competitive benefits package including:
Aro Biotherapeutics is an equal opportunity employer; all qualified applicants will be considered for employment without regard for any characteristic protected by law. Aro Biotherapeutics provides a competitive benefits package.
About Aro Biotherapeutics
Join the team at Aro Biotherapeutics creating breakthrough biotherapeutics based on Centyrin oligonucleotide conjugates. Centyrins are small protein domains based on the fibronectin domains of human Tenascin C that combine the affinity and specificity properties of antibodies with the stability and tissue penetration properties of small molecules. We have engineered Centyrins with an array of specificities for normal and immune cell receptors. By linking Centyrin domains together genetically, we have created multi-specific binders that retain a small footprint to enable excellent tissue penetration. Engineered for high stability, multi-specific Centyrins are readily expressed and purified from E. coli or mammalian cells.
We are developing a platform for delivery of an array of intracellularly active payloads with a focus on oligonucleotides. Our team has built a strong set of in vitro and in vivo data validating the utility of Centyrins for receptor specific uptake in a variety of cell types. Centyrin conjugate mediated delivery provides the foundation for access to a set of intracellular targets that have long been considered undruggable.
Aro is building a wholly owned portfolio of Centyrin oligonucleotide conjugates for genetic and autoimmune diseases and developing a partnered portfolio of Centyrin conjugates for payload delivery in a variety of disease areas. Led by an experienced and exceptional team, Aro is backed by an exceptional syndicate that supports our commitment to advancing drug candidates with the potential to improve patient’s lives and to building an ideal environment for scientific and leadership growth.